<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We undertook an analysis of 2,150 recipients of bone marrow transplant (BMT) at the University of Minnesota to determine the incidence of post-BMT malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MNs) </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty-one patients developed 53 MNs, compared with 4.3 expected from general population rates (standardized incidence ratio [SIR], 11.6, 95% confidence interval [CI], 8.2-14.5) </plain></SENT>
<SENT sid="2" pm="."><plain>These included 22 occurrences of B-cell <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> (BLPD), 17 solid nonhematopoietic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, 10 <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 1 <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 2 non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), and 1 Hodgkin's disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The estimated actuarial incidence of any post-BMT <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> was 9.9% +/- 2.3% at 13 years posttransplant </plain></SENT>
<SENT sid="4" pm="."><plain>The cumulative probability of BLPD plateaued at 1.6% +/- 0.3% by 4 years from transplant and factors independently associated with increased risk included in vitro T-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> of marrow (relative risk (RR) = 11.9, P &lt; .001), HLA mismatch (RR = 8.9, P &lt; .001), use of antithymocyte globulin (ATG) for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> (GVHD) prophylaxis (RR = 5.9, P &lt; .001) or in the preparative regimen (RR = 3.1, P = .03) and primary <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> (RR = 2.5, P = .06) </plain></SENT>
<SENT sid="5" pm="."><plain>The cumulative probability of developing solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> was 5.6% +/- 2.2% at 13 years from BMT </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0002861'>Malignant melanomas</z:hpo> were the most common (SIR, 10.3, 95% CI 1.9 to 25.4) </plain></SENT>
<SENT sid="7" pm="."><plain>The actuarial incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> plateaued at 2.1% +/- 0.8% at 9 years and was seen most often in older patients receiving autologous peripheral blood stem cells for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> or NHL </plain></SENT>
<SENT sid="8" pm="."><plain>These data document that BMT recipients are at an increased risk of later <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, which may add significant morbidity and mortality to the transplant process </plain></SENT>
<SENT sid="9" pm="."><plain>Methods for screening and identification of individuals at increased risk need to be addressed in future studies </plain></SENT>
</text></document>